Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
CagriSema is Novo Nordisk's investigational once-weekly fixed-dose co-formulation of cagrilintide 2.4 mg (long-acting amylin analog) with semaglutide 2.4 mg (GLP-1 receptor agonist) for chronic weight management. Unlike the other grey-market blends, it has a proper Phase 3 clinical program. Novo Nordisk filed an FDA NDA in December 2025; as of April 2026 it is under FDA review and not yet approved.
Lowest Price
$70.99
Highest Price
$149.00
Average Price
$118.60
Potential Savings
77%
across 5 options
0 of 5 vendors are lab-verified for CagriSema
We cross-check each vendor's Certificate of Analysis against the issuing lab's own verification portal — so “cheapest” isn't the only signal.
Best price trend
Lowest $/mg for CagriSema · last 43 days
$6.45/mg
▼ 64% vs 43d ago
Trust grade first, cheapest within grade
blend · 10mgprofoundaminos.com· price updated today
Lot 2025-04-31· tested 2025-05-02
$129.00−23%
$99.00$9.90/mg
34% more per mg
blend · 5mgcertified-pep.com· price updated today
$28.80/mg
77% more per mg
blend · 20mgamc-essentials.com· price updated today
$6.50/mg
blend · 10mgmodernresearchpeptides.net· price updated yesterday
$7.10/mg
8% more per mg
blend · 20mgpolarispeptides.com· price updated yesterday
$7.45/mg
13% more per mg
blend · 10mgsimplepeptide.com· price updated today
Lot 02-21101-02905-P· tested 2025-09-29
$17.80/mg
63% more per mg
blend · 10mgalphaomegapeptide.com· price updated today
$17.80/mg
63% more per mg
Check formulation: Lyophilized powder requires reconstitution before use. Pre-mixed solutions are more convenient but may have a shorter shelf life and higher prices.
Compare per-mg cost: Different strengths and quantities make direct price comparison difficult. Calculate the per-milligram cost to find the true best value.
Verify COAs: Look for vendors that publish per-batch Certificates of Analysis from named, accredited labs. Every vendor on this page is verified for endotoxin testing — not just HPLC purity.
Phase 3 REDEFINE program: REDEFINE-1 (obesity without T2D, 68 weeks, n=3,417) reported 20.4% mean weight loss on CagriSema vs 3.0% placebo (22.7% under full-adherence analysis), published NEJM June 2025. REDEFINE-2 (obesity with T2D) reported ~13.7% weight loss vs 3.4% placebo. REDEFINE-3 is an ongoing cardiovascular outcomes trial. FDA NDA filed December 2025; PDUFA decision expected around October 2026.
This platform provides informational tools only, not medical advice.
Prices verified as of June 2026. Actual prices may vary. For research use only.
Prices are estimates and may vary. For research use only. We may earn a commission on purchases through affiliate links. Not medical advice.
Disclosed Labs